Objective
The widening gap between Pharmaceutical R&D spending and the approval of innovative medicines is a matter of concern both in the US, and in the EU and forms the basis for FP6 topic LSH-2005-1.2.1-3. This project proposes a comprehensive approach to develop a new, safe and more effective medicine that reduces (anti-angiogenic) pathological blood vessel formation. Overgrowth of blood vessels causes a.o. solid tumour growth, ocular neovascularization (diabetic retinopathy and macular degeneration) and rheumatoid arthritis. The proposed drug target is Placental Growth Factor (PlGF) and the candidate drug is a humanized neutralizing monoclonal antibody. This drug target selection is based on: 1) recent basic research at the Flanders Interuniv. Inst. for Biotechn. (VIB-3, Belgium) on the role of PlGF in pathological angiogenesis; 2) intellectual property owned by or licensed to ThromboGenics (TX/TG, Ireland); 3) relevant 'translational research' by most of the partners (BioInvent, BI, Sweden; TX/TG; VIB-3; Cardiff University, CU, UKi) that established proof of concept in experimental animal models that inhibition of PlGF reduced solid tumour growth and improved ocular neovascularization and arthritis; 4) initial 'critical path research' experience at the preclinical level (BI, TX/TG, VIB-3, Charité Berlin, Germany; University Hospital Leuven, Belgium; and CU); and 5) GMP manufacturing capabilities (BI). Although the development of anti-angiogenic compounds has thus far been dominated by US-based biopharmaceutical research, the proposed European Consortium possesses unique assets (both know-how and intellectual property) to play a dominant role in the development of new, safer and more effective anti-angiogenic medicines. This SME driven STREP could lead to significant advancement of the drug candidate program and will form the basis for a long-term industrial and commercial collaboration among the SMEs and their academic collaborators.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine pharmacology and pharmacy drug discovery
- medical and health sciences clinical medicine rheumatology
- medical and health sciences clinical medicine oncology
- medical and health sciences clinical medicine ophthalmology retinopathy
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP6-2005-LIFESCIHEALTH-7
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
LUND
Sweden
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.